Correlation between $LRP1B$ Mutations and Tumor Mutation Burden in Gastric Cancer

Sizhe Hu, Xiaokang Zhao, Feng Qian, Cancan Jin, and Kaishun Hou

Department of Gastrointestinal Surgery, Affiliated Dongyang People’s Hospital of Wenzhou Medical University, Zhejiang Province 322100, China

Correspondence should be addressed to Sizhe Hu; husizhe@zju.edu.cn

Received 21 July 2021; Accepted 3 September 2021; Published 22 September 2021

Copyright © 2021 Sizhe Hu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. It has been shown that low-density lipoprotein receptor-related protein 1B ($LRP1B$) mutations correlate with tumor mutation burden (TMB) and prognosis in patients with melanoma and non-small-cell lung cancer, while the relationship between $LRP1B$ mutations and TMB in gastric cancer needs further study. This study is aimed at exploring the relationship between $LRP1B$ mutations and TMB in gastric cancer.

Methods. Mutation frequency profiles of the genes in patients with gastric cancer in TCGA-STAD dataset were analyzed by bioinformatics analysis. The relationship among $LRP1B$ mutations, TMB, and patient clinical features in gastric cancer was investigated by the chi-square test. The TMB prediction capacity based on $LRP1B$ mutation status was evaluated by ROC curves.

Results. $LRP1B$ is one of the top 10 genes with high gene mutation frequency in gastric cancer. The mutation status of $LRP1B$ in gastric cancer patients was significantly correlated with age and $TP53$ and $MUC16$ mutation status. The result of ROC curve analysis revealed that the mutation status of $LRP1B$ could be considered as an indicator of the degree of TMB in patients with gastric cancer.

Conclusion. This study presented the relationship between TMB and $LRP1B$ mutations in gastric cancer, providing a novel perspective for gastric cancer prognosis and therapy.

1. Introduction

Gastric cancer is the fourth most common cancer in the world and the second primary cause of cancer-related deaths, accounting for 6.8% of all new cancer cases worldwide. Additionally, gastric cancer patients commonly show poor prognosis status. As reported, only 5% of gastric cancer patients survived for five years or more after prognosis, and the mortality rate accounts for 10% of all cancers [1]. In China, there were 679,100 new gastric cancer cases and 498,000 death cases in 2015, reaching more than half of global gastric cancer deaths [2].

In recent years, immune checkpoint blockade (ICB) therapies, including anti-tumor antibody-4 and/or anti-pd-1, have shown durable antitumor effects in the treatment of cancers [3–5]. Tumor mutation burden (TMB), defined as the total number of mutations (nonsynonymous mutation) detected per million bases in the DNA of tumor cells, is widely referred to as a biomarker correlating with clinical responses to ICB in the treatment of melanoma [6–8], non-small-cell lung cancer [9, 10], colorectal cancer, and gastric cancer [11]. TMB detection is based on extensive next-generation sequencing (NGS) or whole-exome sequencing. Recently, several studies have reported that some simple methods such as single gene mutation detection can be used to predict TMB [12]. Numerous studies have shown that mutations in genomic integrity-related genes such as $TP53$ [13] and $ATR$ [14] may lead to genomic instability and thus contribute to a high genomic mutation rate. Besides, mutations of these genes have been reported to be related to TMB [6, 9, 15]. Therefore, studying the correlation between the mutations of key genes and TMB in gastric cancer patients is conducive to the guidance of immunotherapy on gastric cancer patients.

Low-density lipoprotein receptor-related protein 1B ($LRP1B$) is a recognized tumor suppressor gene that encodes an endocytosed ldl receptor. $LRP1B$ expression is reduced in many cancers, and it is a common mutant gene in human cancers [15–17]. Among the studies on $LRP1B$, it was found that $LRP1B$ plays an important role and may serve as a
prognostic marker for cancer during the development of various cancers including gastric cancer [18, 19]. In addition, the significant associations between LRPIB mutations and TMB in lung cancer and melanoma have also been reported [15, 20]. However, there are few studies about the correlation between LRPIB mutation and TMB in gastric cancer.

Here, we explored the mutation status of LRPIB in gastric cancer by analyzing TCGA-STAD dataset. The correlation between clinical features of patients with gastric cancer and LRPIB mutation was analyzed. And it was assessed whether the mutation status of LRPIB could be the predictor for the TMB level in patients with gastric cancer. The findings above were supposed to be useful for guidance of immunotherapy for cancer patients.

2. Materials and Methods

2.1. Data Downloading. The masked somatic mutation data of gastric cancer samples and the corresponding clinical data were downloaded from TCGA database. Using Mmutect2 software [21], the mutation data of 441 samples was extracted. Then, 372 samples with complete clinical information were retained for later analysis.

2.2. Statistical Analysis of Mutation Information. R packages Maftools [22] and GenVisR [23] were used to analyze the frequency and mutation type of mutant genes in gastric cancer and visualize the analysis results in the form of histogram and waterfall diagrams. Differences in the distribution of LRPIB mutant-type versus wild-type samples among different clinical characteristics (gender, age, survival status, grade, stage, T, N, M, KRAS mutation, TP53 mutation, and MUC16 mutation) were analyzed by the chi-square test. P < 0.05 was considered statistically significant.

2.3. Correlation Analysis of LRPIB Mutations and TMB. According to the definition of TMB, the TMB values of 372 gastric cancer samples in TCGA were calculated, and the gastric cancer samples were divided into high-TMB and low-TMB groups taking the median value as the threshold. Kaplan-Meier survival analysis was performed for the high- and low-TMB groups using the R package survival. The analysis results were tested by the log-rank test, and P < 0.05 was considered statistically significant.

The distribution of samples with different KRAS, TP53, MUC16, and LRPIB mutation statuses in the high- and low-TMB groups was analyzed by the chi-square test, and P < 0.05 was considered to indicate a significant difference in distribution. To assess the accuracy of LRPIB mutation status in predicting the high and low level of TMB, the area under the curve (AUC) was analyzed and calculated by the ROC curve.

3. Results

3.1. The Mutation Status of LRPIB in the Gastric Cancer Genome. The top 20 genes with mutation frequency were visualized by analyzing mutation data from 372 gastric cancer patients in TCGA-STAD dataset (Figure 1). LRPIB with the 7th highest mutation frequency among 20 genes performed a relatively higher mutation frequency (0.176). To investigate the role of LRPIB mutations in gastric cancer, we analyzed the connection between LRPIB mutations and several important clinicopathological features as well as some important biomarker genes in gastric cancer patients. The results showed a significant difference (P < 0.05) in the mutation status of LRPIB between patients ≥ 60 years old and <60 years old. Besides, it was also shown that LRPIB mutations were significantly correlated with mutations in TP53 and MUC16 (Table 1). Based on the above analysis results, the frequency of LRPIB mutation was high in patients with gastric cancer, and distribution of LRPIB mutation was significantly different in patients among different age periods and with different TP53 and MUC16 mutation statuses.

3.2. LRPIB Mutations Are Associated with TMB. To explore the effects of TMB on gastric cancer prognosis, survival analysis was conducted on the high- and low-TMB groups based on TCGA-STAD dataset, and the results showed a significant difference at the prognosis between the high- and low-TMB groups, where the high-TMB group showed relatively optimal survival status (Figure 2). LRPIB mutations have been reported to be significantly associated with TMB [15, 24]. We analyzed the relationship between LRPIB, KRAS, TP53, and MUC16 mutations and TMB by statistical analysis. The results showed that there were significant differences in the distribution of mutation status of LRPIB, KRAS, TP53, and MUC16 genes in patients with gastric cancer in the high- and low-TMB groups (Table 2). Mutations in KRAS, TP53, and MUC16 have been proven to play an important role in the prognosis of gastric cancer and are closely related to TMB. Based on the above, we concluded that there is a significant correlation between LRPIB and TMB.

3.3. The Predictive Value of the Mutation of LRPIB to TMB Value in Gastric Cancer. To further explore whether LRPIB mutations could effectively predict the TMB level in gastric cancer patients, the ROC curve was plotted on LRPIB expression based on TCGA-STAD database. The result demonstrated that the AUC value was 0.602 with 95% confidence interval of 0.550-0.655, which indicated that the level of TMB could be predicted effectively by the LRPIB mutation status of gastric cancer patients (Figure 3). The above results indicated that LRPIB mutation had a certain predictive effect on the level of TMB, which may provide new ideas for later targeted therapy and immunotherapy of gastric cancer.

4. Discussion

In this study, we found that LRPIB is one of the top 20 genes with mutation frequency in gastric cancer through the analysis of mutation data from gastric cancer patients in TCGA-STAD dataset. In the correlation analysis of LRPIB mutation and clinical features of gastric cancer patients, it was found that the mutation of LRPIB was significantly correlated with age, TP53 mutation, and MUC16 mutation. TP53 is the most
common somatic mutation in human cancers, and tumors with TP53 mutations in breast cancer often perform higher invasive and metastatic potential [25]. It has been reported that the mutation frequency of TP53 was significantly higher in patients with liver metastasis of gastric cancer than in gastric cancer patients without liver metastasis [26]. MUC16 encodes cancer antigen 125, a commonly mutated gene in gastric cancer, and its mutation is associated with higher TMB [27]. Our results therefore imply that LRPIB mutations in gastric cancer may indicate TMB mutations and are closely related to the progression of gastric cancer.

TMB is a novel predictive biomarker with a good response to immunotherapy and a quantitative measure approach to quantify the total number of somatic nonsynonymous mutations per megabit of the genome in cancer cell DNA [28]. Zhou et al. [29] studied the effect of KIAA1211 mutations and TMB on the prognosis of non-small-cell lung cancer patients and performed survival analysis, demonstrating that both TMB level and high expression of KIAA1211 are related to a good prognostic factor for non-small-cell lung cancer, and similarly, KIAA1211 mutant frequency is positively correlated with TMB level. In this study, the relationship between LRPIB mutations and TMB in gastric cancer patients from TCGA database was analyzed, and it was found that LRPIB mutations were significantly associated with TMB. In addition, we found that the LRPIB mutation in gastric cancer patients in TCGA-STAD dataset could predict the level of TMB in patients to some extent by ROC curve analysis. In a previous study, Chen et al. [30] found that significant mutations of LRPIB in melanoma and non-small-cell lung cancer were associated with their prognosis and that patients with LRPIB mutations had higher level of TMB and better immunotherapeutic efficacy. Although this paper analyzed and discussed the correlation between LRPIB and TMB in melanoma and non-small-cell cancer, the major conclusion is consistent with our research. In summary, LRPIB mutations can indicate the degree of TMB in gastric cancer. In conclusion, LRPIB could be used as a potential biomarker in patients with gastric cancer.

This study found that LRPIB was mutated more frequently in gastric cancer and was significantly correlated with TMB. This finding may provide new ideas for the role of LRPIB mutations in the prognosis and treatment of gastric cancer. Although this research has a preliminary study on the relationship between LRPIB and TMB and achieved
some progress, it needs further research. Therefore, the role of LRP1B mutations and TMB in the prognosis after immunotherapy in gastric cancer patients can be further explored in subsequent studies. Survival analysis and other experiments can be used to explore the effect of LRP1B and TMB on the overall survival and progression-free survival of gastric cancer patients. In conclusion, this study provides new

| Table 1: Relationship between LRP1B gene mutation status and clinical characteristics in patients with gastric cancer. |
|---------------------------------------------------------------|
|                        | LRP1B MUT (n = 112) | LRP1B WT (n = 260) | P value |
|-------------------------|---------------------|--------------------|---------|
| Gender                  |                     |                    |         |
| Female                  | 36 (32.1%)          | 104 (40.0%)        | 0.187   |
| Male                    | 76 (67.9%)          | 156 (60.0%)        |         |
| Age (years)             |                     |                    |         |
| Age < 60                | 25 (22.3%)          | 91 (35.0%)         | 0.021   |
| Age ≥ 60                | 87 (77.7%)          | 169 (65.0%)        |         |
| Event                   |                     |                    |         |
| Yes                     | 39 (34.8%)          | 90 (34.6%)         | 1       |
| No                      | 73 (65.2%)          | 170 (65.4%)        |         |
| Grade                   |                     |                    |         |
| G1                      | 1 (0.9%)            | 7 (2.7%)           | 0.462   |
| G2                      | 36 (32.1%)          | 90 (34.6%)         |         |
| G3                      | 75 (67.0%)          | 163 (62.7%)        |         |
| Stage                   |                     |                    |         |
| Stage I                 | 14 (12.5%)          | 31 (11.9%)         | 0.883   |
| Stage II                | 34 (30.4%)          | 86 (33.1%)         |         |
| Stage III               | 50 (44.6%)          | 117 (45.0%)        |         |
| Stage IV                | 14 (12.5%)          | 26 (10.0%)         |         |
| T                       |                     |                    |         |
| T1                      | 7 (6.2%)            | 10 (3.8%)          | 0.389   |
| T2                      | 17 (15.2%)          | 56 (21.5%)         |         |
| T3                      | 54 (48.2%)          | 125 (48.1%)        |         |
| T4                      | 34 (30.4%)          | 69 (26.5%)         |         |
| N                       |                     |                    |         |
| N0                      | 39 (34.8%)          | 78 (30.0%)         | 0.565   |
| N1                      | 26 (23.2%)          | 73 (28.1%)         |         |
| N2                      | 21 (18.8%)          | 57 (21.9%)         |         |
| N3                      | 26 (23.2%)          | 52 (20.0%)         |         |
| M                       |                     |                    |         |
| M0                      | 103 (92.0%)         | 242 (93.1%)        | 0.872   |
| M1                      | 9 (8.0%)            | 18 (6.9%)          |         |
| KRAS                    |                     |                    |         |
| Mut                     | 10 (8.9%)           | 22 (8.5%)          | 1       |
| Wild                    | 102 (91.1%)         | 238 (91.5%)        |         |
| TP53                    |                     |                    |         |
| Mut                     | 62 (55.4%)          | 112 (43.1%)        | 0.039   |
| Wild                    | 50 (44.6%)          | 148 (56.9%)        |         |
| MUC16                   |                     |                    |         |
| Mut                     | 67 (59.8%)          | 73 (28.1%)         | <0.001  |
| Wild                    | 45 (40.2%)          | 187 (71.9%)        |         |

Figure 2: Survival analysis of high- and low-TMB groups in TCGA-STAD dataset.

| Table 2: Correlation between gene mutation and TMB. |
|---------------------------------------------------|
| Low TMB (n = 186)        | High TMB (n = 186) | P value |
|--------------------------|--------------------|---------|
| KRAS                     |                    |         |
| Mut                      | 7 (3.8%)           | 25 (13.4%) | 0.001 |
| Wild                     | 179 (96.2%)        | 161 (86.6%) |     |
| TP53                     |                    |         |
| Mut                      | 75 (40.3%)         | 99 (53.2%)  | 0.016 |
| Wild                     | 111 (59.7%)        | 87 (46.8%)  |     |
| LRP1B                    |                    |         |
| Mut                      | 32 (17.2%)         | 80 (43.0%)  | <0.001 |
| Wild                     | 154 (82.8%)        | 106 (57.0%) |     |
| MUC16                    |                    |         |
| Mut                      | 36 (19.4%)         | 104 (55.9%)  | <0.001 |
| Wild                     | 150 (80.6%)        | 82 (44.1%)   |     |

Figure 3: Predictive value of LRP1B mutations to the level of TMB in gastric cancer patients from TCGA-STAD dataset.
ideas for the subsequent treatment of gastric cancer and also lays a foundation for subsequent in-depth studies.

**Data Availability**

The data used to support the findings of this study are included within the article. The data and materials in the current study are available from the corresponding author on reasonable request.

**Disclosure**

The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Conflicts of Interest**

The authors declare no conflicts of interest.

**Authors’ Contributions**

All authors contributed to data analysis, drafted and revised the article, gave the final approval of the version to be published, and agreed to be accountable for all aspects of the work. Sizhe Hu and Xiaokang Zhao contributed equally to this work.

**Acknowledgments**

This study was supported by the funds from the Jinhua Science and Technology Development Plans (Grant number 2021-4-143).

**References**

[1] Y. Lu, L. Li, G. Wu, H. Zhuo, G. Liu, and J. Cai, “Effect of PI3K/Akt signaling pathway on PRAS40Thr246 phosphorylation in gastric cancer cells,” *Iranian Journal of Public Health*, vol. 48, no. 12, pp. 2196–2204, 2019.

[2] H. Cai, C. Jing, X. Chang et al., “Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing,” *Journal of Translational Medicine*, vol. 17, no. 1, p. 189, 2019.

[3] H. Borghaei, L. Paz-Ares, L. Horn et al., “Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer,” *The New England Journal of Medicine*, vol. 373, no. 17, pp. 1627–1639, 2015.

[4] B. Escudier, R. J. Motzer, P. Sharma et al., “Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025,” *European Urology*, vol. 72, no. 3, pp. 368–376, 2017.

[5] J. D. Wolchok, V. Chiarion-Sileni, R. Gonzalez et al., “Overall survival with combined nivolumab and ipilimumab in advanced melanoma,” *The New England Journal of Medicine*, vol. 377, no. 14, pp. 1345–1356, 2017.

[6] E. M. van Allen, D. Miao, B. Schilling et al., “Genomic correlates of response to CTLA-4 blockade in metastatic melanoma,” *Science*, vol. 350, no. 6257, pp. 207–211, 2015.

[7] W. Hugo, J. M. Zaretsky, L. Sun et al., “Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma,” *Cell*, vol. 165, no. 1, pp. 35–44, 2016.

[8] A. Snyder, V. Makarov, T. Merghoub et al., “Genetic basis for clinical response to CTLA-4 blockade in melanoma,” *The New England Journal of Medicine*, vol. 371, no. 23, pp. 2189–2199, 2014.

[9] M. D. Hellmann, T. Nathanson, H. Rizvi et al., “Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer,” *Cancer Cell*, vol. 33, no. 5, pp. 843–852.e4, 2018, e844.

[10] N. A. Rizvi, M. D. Hellmann, A. Snyder et al., “Cancer immunology: Mutation landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer,” *Science*, vol. 348, no. 6230, pp. 124–128, 2015.

[11] D. T. Le, J. N. Durham, K. N. Smith et al., “Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade,” *Science*, vol. 357, no. 6349, pp. 409–413, 2017.

[12] G. Gao, W. Liao, Q. Ma, B. Zhang, Y. Chen, and Y. Wang, “KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma,” *Lung Cancer*, vol. 149, pp. 41–45, 2020.

[13] G. Stracquadanio, X. Wang, M. D. Wallace et al., “The importance of p53 pathway genetics in inherited and somatic cancer genomes,” *Nature Reviews. Cancer*, vol. 16, no. 4, pp. 251–265, 2016.

[14] J. C. Saldivar, D. Cortez, and K. A. Cimprich, “The essential kinase ATR: ensuring faithful duplication of a challenging genome,” *Nature Reviews. Molecular Cell Biology*, vol. 18, no. 10, pp. 622–636, 2017.

[15] H. Chen, W. Chong, Q. Wu, Y. Yao, M. Mao, and X. Wang, “Association of LRP1B mutation with tumor mutation burden and outcomes in melanoma and non-small lung cancer patients treated with immune check-point blockades,” *Frontiers in Immunology*, vol. 10, p. 1113, 2019.

[16] E. Tabouret, M. Labussiere, A. Alentorn, Y. Schmitt, Y. Marie, and M. Sanson, “LRP1B deletion is associated with poor outcome for glioblastoma patients,” *Journal of the Neurological Sciences*, vol. 358, no. 1-2, pp. 440–443, 2015.

[17] R. Beroukhim, C. H. Mermel, D. Porter et al., “The landscape of somatic copy-number alteration across human cancers,” *Nature*, vol. 463, no. 7283, pp. 899–905, 2010.

[18] J. Zhao, C. Xiang, R. Zhao et al., “Clinicopathologic features and genomic analysis of pulmonary blastomatoid carcinosarcoma,” *BMC Cancer*, vol. 20, no. 1, p. 248, 2020.

[19] H. Wang, L. Shen, Y. Li, and J. Lv, “Integrated characterisation of cancer genes identifies key molecular biomarkers in stomach adenocarcinoma,” *Journal of Clinical Pathology*, vol. 73, no. 9, pp. 579–586, 2020.

[20] S. Lan, H. Li, Y. Liu et al., “Erratum to ‘Somatic mutation of LRP1B is associated with tumor mutational burden in patients with lung cancer’ [Lung Cancer 132 (June) (2019) 154-156],” *Lung Cancer*, vol. 138, p. 142, 2019.

[21] D. I. Benjamin, T. Sato, L. Lichtenstein, C. Stewart, and K. Cibulskis, *Calling Somatic SNVs and Indels with Mutect2*, 2019, https://www.biorxiv.org/content/10.1101/861054v1.

[22] A. Mayakonda, D. C. Lin, Y. Assenov, C. Plass, and H. P. Koeffler, “Maftools: efficient and comprehensive analysis of somatic variants in cancer,” *Genome Research*, vol. 28, no. 11, pp. 1747–1756, 2018.
[23] Z. L. Skidmore, A. H. Wagner, R. Lesurf et al., "GenVisR: genomic visualizations in R," Bioinformatics, vol. 32, no. 19, pp. 3012–3014, 2016.

[24] F. Liu, W. Hou, J. Liang, L. Zhu, and C. Luo, "LRP1B mutation: a novel independent prognostic factor and a predictive tumor mutation burden in hepatocellular carcinoma," Journal of Cancer, vol. 12, no. 13, pp. 4039–4048, 2021.

[25] L. Silwal-Pandit, H. M. Vollan, D. A. Quigley, V. Kristensen, and A. Langer, "Correction: TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance," Clinical Cancer Research, vol. 21, no. 6, p. 1502, 2015.

[26] N. Ikari, A. Serizawa, S. Mitani, M. Yamamoto, and T. Furukawa, "Near-comprehensive resequencing of cancer-associated genes in surgically resected metastatic liver tumors of gastric cancer," The American Journal of Pathology, vol. 189, no. 4, pp. 784–796, 2019.

[27] P. Schuetz, R. Bolliger, M. Merker et al., "Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials," Expert Review of Anti-Infective Therapy, vol. 16, no. 7, pp. 555–564, 2018.

[28] Y. Kwak, A. N. Seo, H. E. Lee, and H. S. Lee, "Tumor immune response and immunotherapy in gastric cancer," Journal of Pathology and Translational Medicine, vol. 54, no. 1, pp. 20–33, 2020.

[29] M. Zhou, J. Fan, Z. Li et al., "Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer," Respiratory Research, vol. 20, no. 1, p. 248, 2019.

[30] H. Chen, W. Chong, Q. Wu, Y. Yao, M. Mao, and X. Wang, "Corrigendum: association of LRP1B mutation with tumor mutation burden and outcomes in melanoma and non-small cell lung cancer patients treated with immune check-point blockades," Frontiers in Immunology, vol. 10, p. 1523, 2019.